Which of the following describes the recommended approach to noncompliance in clinical trials?

Boost your GCP E6 (R3) exam readiness. Improve your understanding with engaging, insightful questions. Test yourself with hints and detailed explanations. Prepare effectively!

Multiple Choice

Which of the following describes the recommended approach to noncompliance in clinical trials?

In Good Clinical Practice, managing noncompliance is about a proactive, quality-focused process designed to protect participants and ensure reliable data. When noncompliance occurs—especially if it’s serious—the emphasis is on avoiding recurrence and promptly addressing the issue. This means identifying the root cause, implementing corrective actions to fix the immediate problem, and putting preventive actions in place to prevent it from happening again. It also involves strengthening training, updating procedures, and enhancing monitoring to catch similar issues early. All steps should be documented and proportionate to the risk, and relevant parties such as the sponsor, the ethics committee or IRB, and regulators should be informed as appropriate. Depending on the situation, actions may include additional monitoring, protocol amendments, or even temporarily halting site activities, but the goal is to prevent recurrence and protect participants, not to punish sites. This approach is preferred over waiting for warnings or ignoring issues, as it supports ongoing trial integrity and participant safety.

In Good Clinical Practice, managing noncompliance is about a proactive, quality-focused process designed to protect participants and ensure reliable data. When noncompliance occurs—especially if it’s serious—the emphasis is on avoiding recurrence and promptly addressing the issue. This means identifying the root cause, implementing corrective actions to fix the immediate problem, and putting preventive actions in place to prevent it from happening again. It also involves strengthening training, updating procedures, and enhancing monitoring to catch similar issues early. All steps should be documented and proportionate to the risk, and relevant parties such as the sponsor, the ethics committee or IRB, and regulators should be informed as appropriate. Depending on the situation, actions may include additional monitoring, protocol amendments, or even temporarily halting site activities, but the goal is to prevent recurrence and protect participants, not to punish sites. This approach is preferred over waiting for warnings or ignoring issues, as it supports ongoing trial integrity and participant safety.

More practice questions